key: cord-0825001-75dhkcvb
authors: Ye, Chengjin; Chiem, Kevin; Park, Jun-Gyu; Oladunni, Fatai; Platt, Roy Neal; Anderson, Tim; Almazan, Fernando; de la Torre, Juan Carlos; Martinez-Sobrido, Luis
title: Rescue of SARS-CoV-2 from a single bacterial artificial chromosome
date: 2020-07-22
journal: bioRxiv
DOI: 10.1101/2020.07.22.216358
sha: 577cc70f4170dca961e0278a1a66fa8f3e1a7091
doc_id: 825001
cord_uid: 75dhkcvb

An infectious coronavirus disease 2019 (COVID-19) emerged in the city of Wuhan (China) in December 2019, causing a pandemic that has dramatically impacted public health and socioeconomic activities worldwide. A previously unknown coronavirus, Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2), has been identified as the causative agent of COVID-19. To date, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines or therapeutics available for the prevention or treatment of SARS-CoV-2 infection and/or associated COVID-19 disease, which has triggered a large influx of scientific efforts to develop countermeasures to control SARS-CoV-2 spread. To contribute to these efforts, we have developed an infectious cDNA clone of the SARS-CoV-2 USA-WA1/2020 strain based on the use of a bacterial artificial chromosome (BAC). Recombinant (r)SARS-CoV-2 was readily rescued by transfection of the BAC into Vero E6 cells. Importantly, the BAC-derived rSARS-CoV-2 exhibited growth properties and plaque sizes in cultured cells comparable to those of the SARS-CoV-2 natural isolate. Likewise, rSARS-CoV-2 showed similar levels of replication to that of the natural isolate in nasal turbinates and lungs of infected golden Syrian hamsters. This is, to our knowledge, the first BAC based reverse genetics system for the generation of infectious rSARS-CoV-2 that displays similar features in vivo to that of a natural viral isolate. This SARS-CoV-2 BAC-based reverse genetics will facilitate studies addressing several important questions in the biology of SARS-CoV-2, as well as the identification of antivirals and development of vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19 disease.

viruses (10). 76 The ability of generating recombinant viruses using reverse genetics 

Assembly of SARS-CoV-2 genome in the BAC 127 We used a BAC-based approach, similar to the one we previously 128 described for Zika virus (ZIKV) (16-21) to assemble an infectious clone of 129 SARS-CoV-2 based on the USA-WA1/2020 strain (Fig. 1A) . We selected this 130 SARS-CoV-2 strain because it was isolated from an oropharyngeal swab from 131 a patient with respiratory illness in Washington, US. The viral sequence was 132 deposited in PubMed, and the virus isolate was available from BEI 133 Resources. 134 We chemically synthesized the entire viral genome in 5 fragments that were 135 assembled in the pBeloBAC plasmid using unique restriction enzymes and 136 standard molecular biology approaches (Fig. 1B) . After assembly of the 5 137 fragments, the BAC containing the entire viral genome was analyzed by 138 restriction enzyme analysis (Fig. 1C) . To facilitate the assembly of the viral 139 genome and incorporate genetic tags to distinguish the rSARS-CoV-2 from 140 the natural isolate, we introduced two silent mutations in the S (21,895 nt) and 141 matrix, M (26,843 nt) viral genes that removed BstBI and MluI restriction sites, 142 respectively ( Fig. 1B) .

To recover rSARS-CoV-2, we used an experimental approach similar to that 145 we previously described for mammarenaviruses (22) ( Fig. 2A) . Vero E6 cells 146 were transfected with the SARS-CoV-2 BAC, or empty BAC as internal 147 control, and were monitored for the presence of cytopathic effect (CPE), that 148 were evident at 72 h post-transfection (Fig. 2B) with SARS-CoV-2 N (Fig. 2D) . 156 Characterization of rSARS-CoV-2 In vitro 157 We first confirmed the genetic identity of the rescued rSARS-CoV-2. To that 158 end, we used total RNA isolated from rSARS-CoV-2-and SARS-CoV-2-159 infected Vero E6 cells to amplified by RT-PCR a region in the M gene 160 (nucleotides 26,488-27,784), in which a MluI restriction site was removed from 161 the rSARS-CoV-2 cDNA via a silent mutation (Fig. 1B) . As expected, the RT-162 PCR product from SARS-CoV-2-infected cells digested with MluI yielded two 163 fragments with the size of 351 and 946 bp (Fig. 3A, bottom) . In contrast, the 164 RT-PCR product from rSARS-CoV-2-infected cells was not digested with MluI 165 (Fig. 3A, bottom) . We confirmed the mutation introduced in the MluI restriction 166 site in the rSARS-CoV-2 by sanger sequencing (Fig. 3B) . 167 To further characterize the genetic identity of rSARS-CoV-2, we used next 168 generation sequencing (NGS) to determine the complete genome sequence 169 of natural SARS-CoV-2 isolate from BEI Resources, and the rescue rSARS- Next, we compared rSARS-CoV-2 and the natural isolate of SARS-CoV-2 179 with respect their growth properties in Vero E6 cells. Both rSARS-CoV-2 and 180 SARS-CoV-2 made uniform plaques with of similar size (Fig. 3D) . Likewise, 181 both rSARS-CoV-2 and SARS-CoV-2 exhibited similar growth kinetics and 182 peak titers (Fig. 3E) . These results confirmed the genetic identity of the 183 rSARS-CoV-2 and its ability to replicate to the same extent than SARS-CoV-2 184 natural isolate in Vero E6 cells. gene were removed by silent mutation (Fig. 1) . These mutations were 342 introduced to ensure these restriction sites were unique and not present in the 343 viral genome for the assembly of full-length SARS-CoV-2 genome and as 344 molecular markers to distinguish the rescued rSARS-CoV-2 from the natural 345 isolate (Fig. 3) . 346 For the assembly of the entire viral genome in the BAC, fragment 1 was 347 cloned into the pBeloBAC11 plasmid (NEB) linearized by PciI and HindIII 348 digestion (Fig. 1) . By using the preassigned restriction sites in fragment 1, the 349 other 4 fragments were assembled sequentially by using standard molecular 350 biology methods (Fig. 1) Fisher Scientific) using an electroporator (Bio-Rad) with the condition of 2.5kV, 353 600Ω and 10µF. The BAC containing the full-length SARS-CoV-2 genome, 354 which had been analyzed by digestion using the restriction enzymes used to 355 clone into the pBeloBAC 11 (Fig. 1) , was also confirmed by deep sequencing.

Virus rescue experiments were performed as previously described (19). Lungs Nasal turbinates

From the handling of an outbreak by an 477 unknown pathogen in Wuhan to the preparedness and response in the 478 face of the emergence of Covid-19 in Mexico

Wuhan virus), a novel Coronavirus: human-to-human transmission, 484 travel-related cases, and vaccine readiness

Novel coronavirus: how things are in Wuhan

The pandemic in pictures: how coronavirus is changing the 490 world

Fighting against the 493 common enemy of COVID-19: a practice of building a community with 494 a shared future for mankind

COVID-19: A promising cure quality aware, ultra-sensitive variant caller for uncovering cell-600 population heterogeneity from high-throughput sequencing datasets

A program for annotating and predicting the 604 effects of single nucleotide polymorphisms, SnpEff: SNPs in the 605 genome of Drosophila melanogaster strain w1118; iso-2; iso-3

Influenza A virus attenuation by codon 609 deoptimization of the NS gene for vaccine development

Quantitative Analysis of Histological Staining

At 48 h post-infection, Vero E6 cells were fixed for 677 detection of rSARS-CoV-2 by immunofluorescence and the tissue culture 678 supernatant of the scaled-up Vero E6 cells was collected at 72 h. As internal 679 control for this experiment

Images of empty or SARS-CoV-2 BACs transfected Vero E6 681 cells at 72 h post-transfection. Scale bars, 100 μm. C) Viral titers: Tissue 682 culture supernatant from mock (empty BAC) or transfected Vero E6 cells in 683 T75 flask was collected and titrated by immunofluorescence. Data were 684 presented in mean ± SD. LOD: limit of detection. D) IFA: Vero E6 cells (6-well 685 plate format

fixed at 48 h post-infection and viral detection 687 was carried out by using a SARS-CoV cross-reactive monoclonal antibody 688 (1C7) against the N protein (green)

A-B) Genotypic 691 characterization: Vero E6 cells (6-well plate, 10 6 cells/well, triplicates) were 692 mock-infected or infected (MOI 0.01) with rSARS-CoV-2 or the SARS

After 1 h viral adsorption at 37°C, Vero E6 694 cells were washed 3 times with PBS and incubated in post-infection media at 695

At 24 h post-infection, total RNA from Vero E6 cells was extracted and a 696 1,297 bp region of the M gene

The MluI restriction site is 702 underlined in red and the silent mutation introduced to remove the MluI 703 restriction site (T to A) is shown in the black box (B). C) Verification of BAC 704 and rSARS-CoV-2 sequences: The SARS-CoV-2 non-reference allele 705 frequency was calculated by comparing short reads to the reference genome 706 of USA-WA1/2020 reference. All variants were at low frequency in P6 natural 707 isolate (top), BAC (bottom), and rSARS-CoV-2 (middle) with the exception of 708 introduced variants at positions 21,895 and 26,843, which were fixed in the 709 BAC and rSARS-CoV-2 virus. Non-reference alleles present in less than 1% 710 of reads are not shown. D) Plaque phenotype: Vero E6 cells (6-well plate, 711 10 6 cells/well, triplicates) were infected with ~20 PFU of rSARS-CoV-2 (left) or 712 the natural SARS-CoV-2 isolate (right) for 1h at 37°C. After viral adsorption, 713 cells were washed 3 times with PBS and overlaid with 2 ml of post-infection 714 media containing 1% agar. After 72 h incubation at 37°C, cells were fixed and 715 immunostained with the N protein 1C7 monoclonal antibody. D) Growth 716 kinetics: Vero E6 cells (6-well plate

At the indicated times post-infection, 720 tissue culture supernatants were collected and viral titers were assessed by 721 plaque assay (PFU/ml). Data were presented in mean ± SD

Gross pathological lung lesions: 726 Animals were euthanized at 2 and 4 days post-infection, and lungs from 727 mock-infected or infected (rSARS-CoV-2 and SARS-CoV-2) animals were 728 observed for gross pathological changes, including congestion and atelectasis 729 (white arrows) and frothy trachea exudates (black arrows). Scale bars, 1 730 cm. B) Macroscopic pathology scoring analysis: Distributions of 731 pathological lesions, including consolidation, congestion, and atelectasis, 732 were measured using ImageJ and represented as the percent of the total lung 733 surface area (%). Ns, not significant. C-D) Virus titers: Viral titers in the lungs 734 (C) and nasal turbinates (D) of rSARS-CoV-2 and SARS-CoV-2 infected 735 golden Syrian hamsters were determined at days 2 and 4 post-infection

 625 We want to thank Dr. Thomas Moran at the Icahn School of Medicine at 626 Mount Sinai for providing us with the SARS-CoV cross-reactive N monoclonal 627 antibody 1C7. We also want to thank BEI Resources for providing the SARS-